Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Rapamycin (sirolimus, rapamune)

S N Sehgal1, J S Camardo, J A Scarola

  • 1Division of Endothelial Cell and Cytokine Biology, Wyeth-Ayerst Research, Princeton, New Jersey, USA.

Current Opinion in Nephrology and Hypertension
|November 1, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Similar lipid profile but improved long-term outcomes with sirolimus after cyclosporine withdrawal compared to sirolimus with continuous cyclosporine.

Transplantation proceedings·2009
Same author

Sirolimus-mediated prolongation of rat cardiac allograft survival is enhanced by beta1 integrin very late antigen-4 blockade.

Transplantation proceedings·2005
Same author

Sirolimus: its discovery, biological properties, and mechanism of action.

Transplantation proceedings·2003
Same author

Rapamycin: clinical results and future opportunities.

Transplantation·2001
Same author

Temporary treatment with sirolimus and low-trough cyclosporine prevents acute islet allograft rejection, and combination with starch-conjugated deferoxamine promotes islet engraftment in the preclinical pig model.

Transplantation proceedings·2001
Same author

Compromised kidney graft rejection response in Vervet monkeys after withdrawal of immunosuppressants tacrolimus and sirolimus.

Transplantation·2000

Rapamycin, an immunosuppressive drug, is being tested to prevent organ transplant rejection. This review covers its biological effects, how it works, and potential uses in therapy.

Area of Science:

  • Immunology
  • Pharmacology
  • Transplantation

Background:

  • Rapamycin is a novel immunosuppressive agent.
  • It is currently in clinical trials for allograft rejection therapy.

Purpose of the Study:

  • To review the in-vitro biological properties of rapamycin.
  • To summarize the current knowledge on its mechanism of action.
  • To discuss its therapeutic applications in transplantation.

Main Methods:

  • Literature review of in-vitro studies.
  • Analysis of preclinical and clinical trial data.
  • Synthesis of existing research on rapamycin's effects.

Main Results:

  • Rapamycin exhibits significant immunosuppressive properties in vitro.

Related Experiment Videos

  • Its mechanism of action involves the inhibition of key signaling pathways.
  • Demonstrated efficacy in preclinical models of allograft rejection.

    • Conclusions:

    • Rapamycin shows promise as an immunosuppressive agent for preventing allograft rejection.
    • Further clinical trials are essential to establish its safety and efficacy.
    • Rapamycin may offer a new therapeutic option for transplant recipients.